CLINICAL TRIALS AND OBSERVATIONS Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial
نویسندگان
چکیده
1Hematology Department, Ospedale Santa Croce, Cuneo; 2Hematology Department, Università di Udine, Udine; 3Hematology Department, Ospedale Cervello, Palermo, Sicily; 4Hematology Department, Ospedale Regionale Generale, Bolzano; 5Hematology Department, Ospedale Santa Giuseppe Moscati, Taranto; 6Hematology Department, Ospedale Spedali Civili, Brescia; 7Hematology Department, Ospedale Santa Antonio e Biagio, Alessandria; 8Onco-Hematology Department, Ospedale Azienda Sanitaria Locale 5, La Spezia; 9Internal Medicine Department, Ospedale Galliera, Genova; 10Hematology Department, Università di Firenze, Firenze; 11Onco-Hematology Department, Ospedale Pascale, Napoli; 12Hematology Department, Università di Palermo, Palermo, Sicily; 13Hematology Department, Ospedale Santa Camillo Forlanini, Roma; 14Medical Statistics Department, Università di Torino, Torino; 15Hemolymphopathology Department, Università di Bologna, Bologna; 16Hematology Department, Università di Torino, Torino, Italy
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage
Marco Ladetto,1 Federica De Marco,1 Fabio Benedetti,2 Umberto Vitolo,3 Caterina Patti,4 Alessandro Rambaldi,5 Alessandro Pulsoni,6 Maurizio Musso,7 Anna M. Liberati,8 Attilio Olivieri,9 Andrea Gallamini,10 Enrico Pogliani,11 Delia Rota Scalabrini,12 Vincenzo Callea,13 Francesco Di Raimondo,14 Vincenzo Pavone,15 Alessandra Tucci,16 Sergio Cortelazzo,17 Alessandro Levis,18 Mario Boccadoro,1 Ignaz...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas
Patients with peripheral T-cell lymphomas (PTLs) have an extremely poor prognosis when relapsed or refractory to conventional chemotherapy. We have studied alemtuzumab, a humanized anti-CD52 monoclonal antibody, as therapy for patients with heavily pretreated and refractory PTL. Fourteen patients entered the study. All had clinical stage III or IV disease. Patients received a rapidly escalating...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)
Marco Ladetto, Paolo Corradini, Sonia Vallet, Fabio Benedetti, Umberto Vitolo, Maurizio Martelli, Maura Brugiatelli, Paolo Coser, Alessio Perrotti, Ignazio Majolino, Giuseppe Fioritoni, Sergio Morandi, Maurizio Musso, Renato Zambello, Teodoro Chisesi, Nicola Di Renzo, Paolo Vivaldi, Alberto De Crescenzo, Andrea Gallamini, Flavia Salvi, Gino Santini, Carola Boccomini, Marco Sorio, Monica Astolfi...
متن کاملCLINICAL TRIALS AND OBSERVATIONS CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
One thousand two hundred twenty-two patients treated in the Rituximab with CHOP over age 60 years (RICOVER-60) trial were examined for central nervous system (CNS) disease developing during first-line therapy or after a complete or partial remission had been achieved. Patients received 6 or 8 courses of CHOP (cyclophosphamide, adriamycin, vincristine, prednisone) administered every 2 weeks (CHO...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial
This study was designed to test the hypothesis that administration of granulocyte colony-stimulating factor (G-CSF; filgrastim) during induction chemotherapy with CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) or CNOP (doxorubicin replaced with mitoxantrone) in elderly patients with aggressive nonHodgkin lymphoma (NHL) improves time to treatment failure (TTF), complete remission ...
متن کامل